Journal
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
Volume 70, Issue 4, Pages 551-559Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0091-3057(01)00699-2
Keywords
nicotine dependence; nicotine abstinence syndrome; nicotine withdrawal; physical dependence; preclinical models; nicotinic antagonists; rat
Funding
- NIDA NIH HHS [DA08260, DA10714, DA13327] Funding Source: Medline
Ask authors/readers for more resources
Simple, rapid preclinical models of nicotine physical dependence and abstinence syndrome are needed to identify underlying neurobiological mechanisms and screen potential therapies. One such model induces dependence by 7 days of continuous subcutaneous nicotine infusion in the rat. Abstinence is initiated through termination of infusion or injection of nicotinic antagonist drugs. The result is an abstinence syndrome involving a pattern of behaviors somewhat resembling opiate abstinence in the rat as well as weight gain and depressed locomotor activity. The model has met a number of validity criteria and its essential features have been replicated in several laboratories, Several research groups have modified or extended the model by measuring emotional/motivational changes associated with nicotine abstinence such as conditioned aversion, intracranial self-stimulation (ICSS) thresholds and the startle response. Dependence models have been used to identify neurobiological systems that contribute to nicotine dependence, particularly endogenous opiate systems and the mesolimbic dopamine pathway. It is hypothesized that these different systems contribute to different behavioral aspects of nicotine abstinence syndrome. Increasingly used as a preclinical screening tool, the model has proved sensitive to various abstinence-alleviating therapeutic approaches, including some with already demonstrated clinical effectiveness. (C) 2001 Elsevier Science Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available